Kentucky Retirement Systems Buys 1,809 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Kentucky Retirement Systems lifted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 6.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,396 shares of the company’s stock after buying an additional 1,809 shares during the period. Kentucky Retirement Systems’ holdings in GE HealthCare Technologies were worth $2,455,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in GEHC. LGT Financial Advisors LLC lifted its stake in shares of GE HealthCare Technologies by 1,673.3% in the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the period. Capital Performance Advisors LLP bought a new stake in shares of GE HealthCare Technologies in the third quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new stake in shares of GE HealthCare Technologies in the third quarter valued at about $26,000. Darwin Wealth Management LLC bought a new stake in shares of GE HealthCare Technologies in the third quarter valued at about $31,000. Finally, Continuum Advisory LLC lifted its stake in shares of GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after buying an additional 168 shares during the period. Institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on GEHC shares. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. Wells Fargo & Company increased their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Citigroup increased their price target on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $97.67.

GE HealthCare Technologies Stock Performance

NASDAQ GEHC opened at $91.09 on Friday. The firm has a market cap of $41.66 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 3.19 and a beta of 1.15. The company has a 50 day moving average of $85.05 and a 200-day moving average of $85.86. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.19. The company had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. On average, equities analysts forecast that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.